Leuzy, Antoine
Cicognola, Claudia
Chiotis, Konstantinos
Saint-Aubert, Laure
Lemoine, Laetitia
Andreasen, Niels
Zetterberg, Henrik
Ye, Keqiang
Blennow, Kaj
Höglund, Kina
Nordberg, Agneta
Funding for this research was provided by:
Swedish Research Council (05817, 06086)
Article History
Received: 19 October 2018
Accepted: 11 December 2018
First Online: 4 January 2019
Compliance with ethical standards
:
: A.N. has served as a consultant or on advisory boards for GE Healthcare, Merck AB, Lundbeck AB, Neuroscios, Pharmatrophix, TauRX Therapeutics and Eli Lilly. H.Z. has served on advisory boards for Eli Lilly and Roche Diagnostics, and has received travel support from Teva. K.B. has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer and Roche Diagnostics. H.Z. and K.B. are cofounders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. All other authors declare no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.